The role of bactericidal and opsonic activity in immunity against Bordetella pertussis

References

• Chen Z, He Q. Immune persistence after pertussis vaccination. Hum Vaccin Immunother. 2017 Apr 3;13(4):744–756.
   PubMed Web of Science ®Google Scholar
• Domenech de Cellès M, Magpantay FMG, King AA, et al. The impact of past vaccination coverage and immunity on pertussis resurgence. Sci Transl Med. 2018 Mar 28;10(434).
   Web of Science ®Google Scholar
• Burdin N, Handy LK, Plotkin SA. What is wrong with pertussis vaccine immunity? The problem of waning effectiveness of pertussis vaccines. Cold Spring Harb Perspect Biol. 2017 Dec 1;9(12):a029454.
   PubMed Web of Science ®Google Scholar
• Warfel JM, Zimmerman LI, Merkel TJ. Acellular pertussis vaccines protect against disease but fail to prevent infection and transmission in a nonhuman primate model. Proc Natl Acad Sci U S A. 2014 Jan 14;111(2):787–792.
   PubMed Web of Science ®Google Scholar
• Ausiello CM, Cassone A. Acellular pertussis vaccines and pertussis resurgence: revise or replace? mBio. 2014 Jun 10;5(3):e01339–14.
   PubMed Web of Science ®Google Scholar
• Ross PJ, Sutton CE, Higgins S, et al. Relative contribution of Th1 and Th17 cells in adaptive immunity to Bordetella pertussis: towards the rational design of an improved acellular pertussis vaccine. PLoS Pathog. 2013;9(4):e1003264.
   PubMed Web of Science ®Google Scholar
• Brummelman J, Wilk MM, Han WG, et al. Roads to the development of improved pertussis vaccines paved by immunology. Pathog Dis. 2015 Nov;73(8):ftv067.
   PubMed Web of Science ®Google Scholar
• Higgs R, Higgins SC, Ross PJ, et al. Immunity to the respiratory pathogen Bordetella pertussis. Mucosal Immunol. 2012 Sep;5(5):485–500.
   PubMed Web of Science ®Google Scholar
• Locht C. The path to new Pediatric vaccines against pertussis. Vaccines (Basel). 2021 Mar 5;9(3).
   Web of Science ®Google Scholar
• Pertussis. Annual epidemiological report for 2017. Stockholm: ECDC; 2019 [Oct 2022]. Available from: https://www.ecdc.europa.eu/en/publications-data/pertussis-annual-epidemiological-report-2017
   Google Scholar
• Diavatopoulos DA, Mills KHG, Kester KE. PERISCOPE: road towards effective control of pertussis. Lancet Infect Dis. 2019 May;19(5):e179–e186.
   PubMed Web of Science ®Google Scholar
• Lu LL, Suscovich TJ, Fortune SM, et al. Beyond binding: antibody effector functions in infectious diseases. Nat Rev Immunol. 2018 Jan;18(1):46–61.
   PubMed Web of Science ®Google Scholar
• Bjanes E, Nizet V. More than a pore: nonlytic antimicrobial functions of complement and bacterial strategies for evasion. Microbiol Mol Biol Rev. 2021 Feb 17;85(1). DOI:10.1128/MMBR.00177-20.
   PubMed Web of Science ®Google Scholar
• Mellors J, Tipton T, Longet S, et al. Viral evasion of the complement system and its importance for vaccines and therapeutics. Front Immunol. 2020;11:1450.
   PubMed Web of Science ®Google Scholar
• Merle NS, Noe R, Halbwachs-Mecarelli L, et al. Complement system part II: role in immunity. Front Immunol. 2015;6:257.
   PubMed Web of Science ®Google Scholar
• Geurtsen J, Fae KC, van den Dobbelsteen GP. Importance of (antibody-dependent) complement-mediated serum killing in protection against Bordetella pertussis. Expert Rev Vaccines. 2014 Oct;13(10):1229–1240.
   PubMed Web of Science ®Google Scholar
• Ogundele M. Role and significance of the complement system in mucosal immunity: particular reference to the human breast milk complement. Immunol Cell Biol. 2001 Feb;79(1):1–10.
   PubMed Web of Science ®Google Scholar
• Lubbers R, van Essen MF, van Kooten C, et al. Production of complement components by cells of the immune system. Clin Exp Immunol. 2017 May;188(2):183–194.
   PubMed Web of Science ®Google Scholar
• Kulkarni HS, Liszewski MK, Brody SL, et al. The complement system in the airway epithelium: an overlooked host defense mechanism and therapeutic target? J Allergy Clin Immunol. 2018 May;141(5):1582–1586.e1.
   PubMed Web of Science ®Google Scholar
• Pandya PH, Wilkes DS. Complement system in lung disease. Am J Respir Cell Mol Biol. 2014 Oct;51(4):467–473.
   PubMed Web of Science ®Google Scholar
• Persson CG, Erjefält I, Alkner U, et al. Plasma exudation as a first line respiratory mucosal defence. Clin Exp Allergy. 1991 Jan;21(1):17–24.
   PubMed Web of Science ®Google Scholar
• Bolger MS, Ross DS, Jiang H, et al. Complement levels and activity in the normal and LPS-injured lung. Am J Physiol Lung Cell Mol Physiol. 2007 Mar;292(3):L748–59.
   PubMed Web of Science ®Google Scholar
• Watford WT, Ghio AJ, Wright JR. Complement-mediated host defense in the lung. Am J Physiol Lung Cell Mol Physiol. 2000 Nov;279(5):L790–8.
   PubMed Web of Science ®Google Scholar
• Persson C. Humoral First-Line mucosal innate defence in vivo. J Innate Immun. 2020;12(5):373–386.
   PubMed Web of Science ®Google Scholar
• Dolby JM, Vincent WA. Characterization of the antibodies responsible for the ‘bactericidal activity patterns’ of antisera to Bordetella pertussis. Immunology. 1965 May;8(5):499–510.
   PubMed Web of Science ®Google Scholar
• Xing D, Markey K, Gaines Das R, et al. Whole-cell pertussis vaccine potency assays: the Kendrick test and alternative assays. Expert Rev Vaccines. 2014 October 01;13(10):1175–1182.
   PubMed Web of Science ®Google Scholar
• Ackers JP, Dolby JM. The antigen of Bordetella pertussis that induces bactericidal antibody and its relationship to protection of mice. J Gen Microbiol. 1972 Apr;70(2):371–382.
   PubMedGoogle Scholar
• Barnes MG, Weiss AA. Activation of the complement cascade by Bordetella pertussis. FEMS Microbiol Lett. 2003 Mar 28;220(2):271–275.
   PubMed Web of Science ®Google Scholar
• Raeven RH, Pennings JL, van Riet E, et al. Meta-Analysis of Pulmonary Transcriptomes from Differently Primed Mice Identifies Molecular Signatures to Differentiate Immune Responses following Bordetella pertussis Challenge. J Immunol Res. 2017;2017:8512847.
   PubMed Web of Science ®Google Scholar
• Weill JC, Reynaud CA. IgM memory B cells: specific effectors of innate-like and adaptive responses. Curr Opin Immunol. 2020 Apr;63:1–6.
   PubMed Web of Science ®Google Scholar
• Macaulay ME. The IgM and IgG response to Bordetella pertussis vaccination and infection. J Med Microbiol. 1981 Feb;14(1):1–7.
   PubMed Web of Science ®Google Scholar
• Horton RE, Vidarsson G. Antibodies and their receptors: different potential roles in mucosal defense. Front Immunol. 2013;4:200.
   PubMed Web of Science ®Google Scholar
• Lilienthal GM, Rahmöller J, Petry J, et al. Potential of murine IgG1 and human IgG4 to inhibit the classical complement and Fcγ receptor activation pathways. Front Immunol. 2018;9:958.
   PubMed Web of Science ®Google Scholar
• van der Lee S, Sanders EAM, Berbers GAM, et al. Whole-cell or acellular pertussis vaccination in infancy determines IgG subclass profiles to DTaP booster vaccination. Vaccine. 2018 Jan 4;36(2):220–226.
   PubMed Web of Science ®Google Scholar
• Roos A, Bouwman LH, van Gijlswijk-Janssen DJ, et al. Human IgA activates the complement system via the mannan-binding lectin pathway. J Immunol. 2001 Sep 1;167(5):2861–2868.
   PubMed Web of Science ®Google Scholar
• Michaelsen TE, Emilsen S, Sandin RH, et al. Human secretory IgM antibodies activate human complement and offer protection at mucosal surface. Scand J Immunol. 2017 Jan;85(1):43–50.
   PubMed Web of Science ®Google Scholar
• Figueroa JE, Densen P. Infectious diseases associated with complement deficiencies. Clin Microbiol Rev. 1991 Jul;4(3):359–395.
   PubMed Web of Science ®Google Scholar
• Kurvers RA, Westra D, van Heijst AF, et al. Severe infantile Bordetella pertussis pneumonia in monozygotic twins with a congenital C3 deficiency. Eur J Pediatr. 2014 Dec;173(12):1591–1594.
   PubMed Web of Science ®Google Scholar
• Barnum SR. Complement: a primer for the coming therapeutic revolution. Pharmacol Ther. 2017 Apr;172:63–72.
   PubMed Web of Science ®Google Scholar
• Gröndahl-Yli-Hannuksela K, Viander M, Mertsola J, et al. Increased risk of pertussis in adult patients with mannose-binding lectin deficiency. Apmis. 2013 Apr;121(4):311–315.
   PubMed Web of Science ®Google Scholar
• Thiriard A, Raze D, Locht C. Diversion of complement-mediated killing by Bordetella. Microbes Infect. 2018 Oct-Nov;20(9–10):512–520.
   PubMed Web of Science ®Google Scholar
• Barnes MG, Weiss AA. BrkA protein of Bordetella pertussis inhibits the classical pathway of complement after C1 deposition. Infect Immun. 2001 May;69(5):3067–3072.
   PubMed Web of Science ®Google Scholar
• Stefanelli P, Sanguinetti M, Fazio C, et al. Differential in vitro expression of the brkA gene in Bordetella pertussis and Bordetella parapertussis clinical isolates. J Clin Microbiol. 2006 Sep;44(9):3397–3400.
   PubMed Web of Science ®Google Scholar
• Noofeli M, Bokhari H, Blackburn P, et al. BapC autotransporter protein is a virulence determinant of Bordetella pertussis. Microb Pathog. 2011 Sep;51(3):169–177.
   PubMed Web of Science ®Google Scholar
• Marr N, Shah NR, Lee R, et al. Bordetella pertussis autotransporter Vag8 binds human C1 esterase inhibitor and confers serum resistance. PLoS One. 2011;6(6):e20585.
   PubMed Web of Science ®Google Scholar
• Hovingh ES, van den Broek B, Kuipers B, et al. Acquisition of C1 inhibitor by Bordetella pertussis virulence associated gene 8 results in C2 and C4 consumption away from the bacterial surface. PLoS Pathog. 2017 Jul;13(7):e1006531.
   PubMed Web of Science ®Google Scholar
• Brookes C, Freire-Martin I, Cavell B, et al. Bordetella pertussis isolates vary in their interactions with human complement components. Emerg Microbes Infect. 2018 May 9;7(1):81.
   PubMedGoogle Scholar
• Berggård K, Johnsson E, Mooi FR, et al. Bordetella pertussis binds the human complement regulator C4BP: role of filamentous hemagglutinin. Infect Immun. 1997 Sep;65(9):3638–3643.
   PubMed Web of Science ®Google Scholar
• Amdahl H, Jarva H, Haanperä M, et al. Interactions between Bordetella pertussis and the complement inhibitor factor H. Mol Immunol. 2011 Jan;48(4):697–705.
   PubMed Web of Science ®Google Scholar
• Conover MS, Sloan GP, Love CF, et al. The Bps polysaccharide of Bordetella pertussis promotes colonization and biofilm formation in the nose by functioning as an adhesin. Mol Microbiol. 2010 Sep;77(6):1439–1455.
   PubMed Web of Science ®Google Scholar
• Ganguly T, Johnson JB, Kock ND, et al. The Bordetella pertussis Bps polysaccharide enhances lung colonization by conferring protection from complement-mediated killing. Cell Microbiol. 2014 Jul;16(7):1105–1118.
   PubMed Web of Science ®Google Scholar
• Jongerius I, Schuijt TJ, Mooi FR, et al. Complement evasion by Bordetella pertussis: implications for improving current vaccines. J Mol Med (Berl). 2015 Apr;93(4):395–402.
   PubMed Web of Science ®Google Scholar
• Caroff M, Brisson J, Martin A, et al. Structure of the Bordetella pertussis 1414 endotoxin. FEBS Lett. 2000 Jul 14;477(1–2):8–14.
   PubMed Web of Science ®Google Scholar
• Mountzouros KT, Kimura A, Cowell JL. A bactericidal monoclonal antibody specific for the lipooligosaccharide of Bordetella pertussis reduces colonization of the respiratory tract of mice after aerosol infection with B. pertussis. Infect Immun. 1992 Dec;60(12):5316–5318.
   PubMed Web of Science ®Google Scholar
• Niedziela T, Letowska I, Lukasiewicz J, et al. Epitope of the vaccine-type Bordetella pertussis strain 186 lipooligosaccharide and antiendotoxin activity of antibodies directed against the terminal pentasaccharide-tetanus toxoid conjugate. Infect Immun. 2005 Nov;73(11):7381–7389.
   PubMed Web of Science ®Google Scholar
• Kubler-Kielb J, Vinogradov E, Lagergård T, et al. Oligosaccharide conjugates of Bordetella pertussis and bronchiseptica induce bactericidal antibodies, an addition to pertussis vaccine. Proc Natl Acad Sci U S A. 2011 Mar 8;108(10):4087–4092.
   PubMed Web of Science ®Google Scholar
• Robbins JB, Schneerson R, Kubler-Kielb J, et al. Toward a new vaccine for pertussis. Proc Natl Acad Sci U S A. 2014 Mar 4;111(9):3213–3216.
   PubMed Web of Science ®Google Scholar
• Trollfors B, Lagergård T, Taranger J, et al. Serum immunoglobulin G antibody responses to Bordetella pertussis lipooligosaccharide and B. parapertussis lipopolysaccharide in children with pertussis and parapertussis. Clin Diagn Lab Immunol. 2001 Sep;8(5):1015–1017.
   PubMedGoogle Scholar
• Oliver DC, Fernandez RC. Antibodies to BrkA augment killing of Bordetella pertussis. Vaccine. 2001 Oct 12;20(1–2):235–241.
   PubMed Web of Science ®Google Scholar
• Weiss AA, Mobberley PS, Fernandez RC, et al. Characterization of human bactericidal antibodies to Bordetella pertussis. Infect Immun. 1999 Mar;67(3):1424–1431.
   PubMed Web of Science ®Google Scholar
• Gotto JW, Eckhardt T, Reilly PA, et al. Biochemical and immunological properties of two forms of pertactin, the 69,000-molecular-weight outer membrane protein of Bordetella pertussis. Infect Immun. 1993 May;61(5):2211–2215.
   PubMed Web of Science ®Google Scholar
• Lesne E, Cavell BE, Freire-Martin I, et al. Acellular pertussis vaccines induce anti-pertactin bactericidal antibodies which drives the emergence of pertactin-negative strains. Front Microbiol. 2020;11:2108.
   PubMed Web of Science ®Google Scholar
• Keech CA, Gorringe A, Cavell B, et al. 1183. serum bactericidal activity induced by live attenuated pertussis vaccine BPZE1 is comparable to Boostrix™. Open Forum Infect Dis. 2021;8(Supplement_1):S684–S684.
   Google Scholar
• Locht C, Papin JF, Lecher S, et al. Live attenuated pertussis vaccine BPZE1 protects baboons against Bordetella pertussis disease and infection. J Infect Dis. 2017 Jul 1;216(1):117–124.
   PubMed Web of Science ®Google Scholar
• Weingart CL, Keitel WA, Edwards KM, et al. Characterization of bactericidal immune responses following vaccination with acellular pertussis vaccines in adults. Infect Immun. 2000 Dec;68(12):7175–7179.
   PubMed Web of Science ®Google Scholar
• Cole LE, Zhang J, Pacheco KM, et al. Immunological distinctions between acellular and whole-cell pertussis Immunizations of baboons persist for at least one year after acellular vaccine boosting. Vaccines (Basel). 2020 Dec 2;8(4). DOI:10.3390/vaccines8040729.
   PubMed Web of Science ®Google Scholar
• Segal AW. How neutrophils kill microbes. Annu Rev Immunol. 2005;23(1):197–223.
   PubMedGoogle Scholar
• Liew PX, Kubes P. The neutrophil’s role during health and disease. Physiol Rev. 2019 Apr 1;99(2):1223–1248.
   PubMed Web of Science ®Google Scholar
• Andreasen C, Carbonetti NH. Role of neutrophils in response to Bordetella pertussis infection in mice. Infect Immun. 2009 Mar;77(3):1182–1188.
   PubMed Web of Science ®Google Scholar
• Kirimanjeswara GS, Agosto LM, Kennett MJ, et al. Pertussis toxin inhibits neutrophil recruitment to delay antibody-mediated clearance of Bordetella pertussis. J Clin Invest. 2005 Dec;115(12):3594–3601.
   PubMed Web of Science ®Google Scholar
• Goebel EM, Zhang X, Harvill ET. Bordetella pertussis infection or vaccination substantially protects mice against B. bronchiseptica infection. PLoS One. 2009 Aug 26;4(8):e6778.
   PubMed Web of Science ®Google Scholar
• Eby JC, Hoffman CL, Gonyar LA, et al. Review of the neutrophil response to Bordetella pertussis infection. Pathog Dis. 2015 Dec;73(9):ftv081.
   PubMed Web of Science ®Google Scholar
• Andreasen C, Powell DA, Carbonetti NH. Pertussis toxin stimulates IL-17 production in response to Bordetella pertussis infection in mice. PLoS One. 2009 Sep 17;4(9):e7079.
   PubMed Web of Science ®Google Scholar
• Rathore JS, Wang Y. Protective role of Th17 cells in pulmonary infection. Vaccine. 2016 Mar 18;34(13):1504–1514.
   PubMed Web of Science ®Google Scholar
• Solans L, Debrie AS, Borkner L, et al. IL-17-dependent SIgA-mediated protection against nasal Bordetella pertussis infection by live attenuated BPZE1 vaccine. Mucosal Immunol. 2018 Nov;11(6):1753–1762.
   PubMed Web of Science ®Google Scholar
• Allen AC, Wilk MM, Misiak A, et al. Sustained protective immunity against Bordetella pertussis nasal colonization by intranasal immunization with a vaccine-adjuvant combination that induces IL-17-secreting T(RM) cells. Mucosal Immunol. 2018 Nov;11(6):1763–1776.
   PubMed Web of Science ®Google Scholar
• Misiak A, Wilk MM, Raverdeau M, et al. IL-17-producing innate and pathogen-specific tissue resident memory γδ T cells expand in the lungs of Bordetella pertussis-infected mice. J Immunol. 2017 Jan 1;198(1):363–374.
   PubMed Web of Science ®Google Scholar
• Rouleau N, Proust E, Chabaud-Riou M. A novel outbred mouse model to study lung memory immunological response induced by pertussis vaccines. Immunohorizons. 2020 Dec 8;4(12):762–773.
   PubMedGoogle Scholar
• Zurita ME, Wilk MM, Carriquiriborde F, et al. A pertussis outer membrane vesicle-based vaccine induces lung-resident memory CD4 T cells and protection against Bordetella pertussis, including pertactin deficient strains. Front Cell Infect Microbiol. 2019;9:125.
   PubMed Web of Science ®Google Scholar
• Raeven RH, Brummelman J, Pennings JL, et al. Bordetella pertussis outer membrane vesicle vaccine confers equal efficacy in mice with milder inflammatory responses compared to a whole-cell vaccine. Sci Rep. 2016 Dec 1;6(1):38240.
   PubMedGoogle Scholar
• Borkner L, Curham LM, Wilk MM, et al. IL-17 mediates protective immunity against nasal infection with Bordetella pertussis by mobilizing neutrophils, especially Siglec-F(+) neutrophils. Mucosal Immunol. 2021 Sep;14(5):1183–1202.
   PubMed Web of Science ®Google Scholar
• Warfel JM, Merkel TJ. Bordetella pertussis infection induces a mucosal IL-17 response and long-lived Th17 and Th1 immune memory cells in nonhuman primates. Mucosal Immunol. 2013 Jul;6(4):787–796.
   PubMed Web of Science ®Google Scholar
• Zimmerman LI, Papin JF, Warfel J, et al. Histopathology of Bordetella pertussis in the baboon model. Infect Immun. 2018 Nov;86(11). DOI:10.1128/IAI.00511-18.
   PubMed Web of Science ®Google Scholar
• Cundell DR, Kanthakumar K, Taylor GW, et al. Effect of tracheal cytotoxin from Bordetella pertussis on human neutrophil function in vitro. Infect Immun. 1994 Feb;62(2):639–643.
   PubMed Web of Science ®Google Scholar
• Weingart CL, Weiss AA. Bordetella pertussis virulence factors affect phagocytosis by human neutrophils. Infect Immun. 2000 Mar;68(3):1735–1739.
   PubMed Web of Science ®Google Scholar
• Cerny O, Kamanova J, Masin J, et al. Bordetella pertussis adenylate cyclase toxin blocks induction of bactericidal nitric oxide in macrophages through cAMP-dependent activation of the SHP-1 phosphatase. J Immunol. 2015 May 15;194(10):4901–4913.
   PubMed Web of Science ®Google Scholar
• Hazenbos WL, Geuijen CA, van den Berg BM, et al. Bordetella pertussis fimbriae bind to human monocytes via the minor fimbrial subunit FimD. J Infect Dis. 1995 Apr;171(4):924–929.
   PubMed Web of Science ®Google Scholar
• Hellwig SM, Rodriguez ME, Berbers GA, et al. Crucial role of antibodies to pertactin in Bordetella pertussis immunity. J Infect Dis. 2003 Sep 1;188(5):738–742.
   PubMed Web of Science ®Google Scholar
• Aase A, Herstad TK, Merino S, et al. Opsonophagocytic activity and other serological indications of Bordetella pertussis infection in military recruits in Norway. Clin Vaccine Immunol. 2007 Jul;14(7):855–862.
   PubMedGoogle Scholar
• Aase A, Herstad TK, Merino S, et al. Immunization of teenagers with a fifth dose of reduced DTaP-IPV induces high levels of pertussis antibodies with a significant increase in opsonophagocytic activity. Clin Vaccine Immunol. 2011 Aug;18(8):1269–1274.
   PubMedGoogle Scholar
• Hovingh ES, Kuipers B, Bonačić Marinović AA, et al. Detection of opsonizing antibodies directed against a recently circulating Bordetella pertussis strain in paired plasma samples from symptomatic and recovered pertussis patients. Sci Rep. 2018 Aug 13;8(1):12039.
   PubMedGoogle Scholar
• Kroes MM, van Vliet LC, Jacobi RHJ, et al. Long lasting antibodies from convalescent pertussis patients induce ROS production and bacterial killing by human neutrophils. Front Cell Infect Microbiol. 2022;12:888412.
   PubMed Web of Science ®Google Scholar
• Leitner WW, Haraway M, Pierson T, et al. Role of opsonophagocytosis in immune protection against Malaria. Vaccines (Basel). 2020 May 30;8(2). DOI:10.3390/vaccines8020264.
   PubMed Web of Science ®Google Scholar
• Rodriguez ME, Hellwig SM, Hozbor DF, et al. Fc receptor-mediated immunity against Bordetella pertussis. J Immunol. 2001 Dec 1;167(11):6545–6551.
   PubMed Web of Science ®Google Scholar
• James LK, Till SJ. Potential mechanisms for IgG4 inhibition of immediate hypersensitivity reactions. Curr Allergy Asthma Rep. 2016 Mar;16(3):23.
   PubMed Web of Science ®Google Scholar
• Diavatopoulos DA, Edwards KM. What is wrong with pertussis vaccine immunity? Why immunological memory to pertussis is failing. Cold Spring Harb Perspect Biol. 2017 Dec 1;9(12):a029553.
   PubMed Web of Science ®Google Scholar
• Alexander F, Brunt E, Humphries H, et al. Generation of a universal human complement source by large-scale depletion of IgG and IgM from pooled human plasma. Methods Mol Biol. 2022;2414:341–362.
   PubMedGoogle Scholar
• Plotkin SA. Correlates of protection induced by vaccination. Clin Vaccine Immunol. 2010 Jul;17(7):1055–1065.
   PubMed Web of Science ®Google Scholar
• Bottero D, Gaillard ME, Zurita E, et al. Characterization of the immune response induced by pertussis OMVs-based vaccine. Vaccine. 2016 Jun 14;34(28):3303–3309.
   PubMed Web of Science ®Google Scholar
• Mills KH, Ryan M, Ryan E, et al. A murine model in which protection correlates with pertussis vaccine efficacy in children reveals complementary roles for humoral and cell-mediated immunity in protection against Bordetella pertussis. Infect Immun. 1998 Feb;66(2):594–602.
   PubMed Web of Science ®Google Scholar
• Simondon F, Preziosi MP, Yam A, et al. A randomized double-blind trial comparing a two-component acellular to a whole-cell pertussis vaccine in Senegal. Vaccine. 1997 Oct;15(15):1606–1612.
   PubMed Web of Science ®Google Scholar
• Guiso N, Capiau C, Carletti G, et al. Intranasal murine model of Bordetella pertussis infection. I. Prediction of protection in human infants by acellular vaccines. Vaccine. 1999 May 14;17(19):2366–2376.
   PubMed Web of Science ®Google Scholar
• WHO, Expert Committee on Biological Standardization. Recommendations to assure the quality, safety and efficacy of acellular pertussis vaccines. Replacement of Annex 2 of WHO Technical Report Series, No. 878. TRS 979; 2013; Annex 4;187–260. Annex 4: [October 2022]. https://www.who.int/biologicals/vaccines/TRS_979_Annex_4.pdf?ua=1
   Google Scholar
• van Beek LF, de Gouw D, Eleveld MJ, et al. Adaptation of Bordetella pertussis to the respiratory tract. J Infect Dis. 2018 May 25;217(12):1987–1996.
   PubMed Web of Science ®Google Scholar
• Zhang Q, Yin Z, Li Y, et al. Prevalence of asymptomatic Bordetella pertussis and Bordetella parapertussis infections among school children in China as determined by pooled real-time PCR: a cross-sectional study. Scand J Infect Dis. 2014 Apr;46(4):280–287.
   PubMed Web of Science ®Google Scholar
• Gill CJ, Gunning CE, MacLeod WB, et al. Asymptomatic Bordetella pertussis infections in a longitudinal cohort of young African infants and their mothers. Elife. 2021;7:10.
   Google Scholar
• Holubová J, Staněk O, Brázdilová L, et al. Acellular pertussis vaccine inhibits Bordetella pertussis clearance from the nasal mucosa of mice. Vaccines (Basel). 2020 Nov 19;8(4). DOI:10.3390/vaccines8040695.
   PubMed Web of Science ®Google Scholar
• Pinto MV, Merkel TJ. Pertussis disease and transmission and host responses: insights from the baboon model of pertussis. J Infect. 2017 Jun;74(1):S114–s119.
   PubMedGoogle Scholar
• Warfel JM, Beren J, Kelly VK, et al. Nonhuman primate model of pertussis. Infect Immun. 2012 Apr;80(4):1530–1536.
   PubMed Web of Science ®Google Scholar
• de Graaf H, Gbesemete D, Gorringe AR, et al. Investigating Bordetella pertussis colonisation and immunity: protocol for an inpatient controlled human infection model. BMJ Open. 2017 Oct 11;7(10):e018594.
   PubMed Web of Science ®Google Scholar
• de Graaf H, Ibrahim M, Hill AR, et al. Controlled human infection with Bordetella pertussis induces asymptomatic, immunizing colonization. Clin Infect Dis. 2020 Jul 11;71(2):403–411.
   PubMed Web of Science ®Google Scholar
• Bergman I, Basse PH, Barmada MA, et al. Comparison of in vitro antibody-targeted cytotoxicity using mouse, rat and human effectors. Cancer Immunol Immunother. 2000 Jul;49(4–5):259–266.
   PubMed Web of Science ®Google Scholar
• Mattoo S, Cherry JD. Molecular pathogenesis, epidemiology, and clinical manifestations of respiratory infections due to Bordetella pertussis and other Bordetella subspecies. Clin Microbiol Rev. 2005 Apr;18(2):326–382.
   PubMed Web of Science ®Google Scholar
• Naninck T, Coutte L, Mayet C, et al. In vivo imaging of bacterial colonization of the lower respiratory tract in a baboon model of Bordetella pertussis infection and transmission. Sci Rep. 2018 Aug 16;8(1):12297.
   PubMedGoogle Scholar